# Nanobody-drug conjugates for targeting specific GPCR pairs

## TL;DR

This paper introduces nanobody-drug conjugates that can precisely control GPCR signaling by targeting two receptor sites.

## Contribution

The study introduces novel nanobody-small molecule conjugates with logic-gated activity for improved GPCR signaling.

## Key findings

- Nanobody-drug conjugates were created using click chemistry.
- These conjugates showed logic-gated activity at co-expressed receptor pairs.
- They improved signaling profiles compared to traditional ligands.

## Abstract

Bitopic ligands that engage two distinct binding sites offer exciting opportunities for finely tuned control of G protein-coupled receptor signaling. A recent study in PLOS Biology employed click chemistry to generate novel nanobody-small molecule conjugates and demonstrated their logic-gated activity at co-expressed receptor pairs with improved signaling profiles.

Bitopic ligands that engage two distinct binding sites offer exciting opportunities for finely tuned control of G protein-coupled receptor signaling. This Primer explores a recent study in PLOS Biology that reports novel nanobody-small molecule conjugates and demonstrates their logic-gated activity at co-expressed receptor pairs with improved signaling profiles.